Investigational drug · Phase 2
PER-001 Intravitreal Implant
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Retinopathy, Open-angle Glaucoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
2
Any phase or sponsor naming "PER-001 Intravitreal Implant"
First trial start
2023
May 25, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PER-001 Intravitreal Implant", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Retinopathy
- Open-angle Glaucoma
Approved drugs for the same conditions: Glaucoma · Cardiovascular and metabolic · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "PER-001 Intravitreal Implant" as an intervention, largest first.
Perfuse Therapeutics, Inc.Industry
NCT05822245 · 33 participants · Start May 25, 2023 · Primary completion Apr 20, 2025
Drug: PER-001 Intravitreal Implant - Low Dose; PER-001 Intravitreal Implant - High Dose and 1 more · For: Open-angle Glaucoma
Sites: San Francisco, California
Perfuse Therapeutics, Inc.Industry
NCT06003751 · 27 participants · Start Aug 5, 2023 · Primary completion Apr 3, 2025
Drug: PER-001 Intravitreal Implant - Low Dose; PER-001 Intravitreal Implant - High Dose and 1 more · For: Diabetic Retinopathy
Sites: San Francisco, California
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Diabetic Retinopathy
- 4D-1503E10 vg, eyePhase 35 trials
4D Molecular Therapeutics · Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
- TiespectusEYE201, MK-8748Phase 35 trials
EyeBiotech Ltd. · Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization
- Surabgene LomparvovecABBV-RGX-314Phase 32 trials
AbbVie · Diabetic Retinopathy, Neovascular Age-related Macular Degeneration
- TarcocimabTarcocimab tedromer, KSI-301Phase 32 trials
Kodiak Sciences Inc · Wet Age-related Macular Degeneration, Diabetic Retinopathy
- PER-001 Intravitreal Implant - ShamPhase 22 trials
Perfuse Therapeutics, Inc. · Diabetic Retinopathy, Open-angle Glaucoma
- BI 764524Phase 21 trial
Boehringer Ingelheim · Diabetic Retinopathy
- INV-102Phase 21 trial
Invirsa, Inc. · Non-center Involved Diabetic Macular Edema, Non-center Involved Diabetic Macular Edema Associated With Non-proliferative Diabetic Retinopathy, Diabetic Retinopathy
- VX-01Phase 21 trial
Vantage Biosciences Ltd · Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.